Kintsugi CEO Grace Chang says the mental health AI startup’s venture-backed business model became financially unsustainable because of the high cost and lengthy timeline of U.S. Food and Drug Administration regulatory hurdles. Her warning focuses on the burden of FDA requirements for startups building healthcare AI.
Kintsugi, a clinical AI startup, is ending commercial operations and open-sourcing its voice biomarker technology for detecting depression and anxiety. The company says high costs and lengthy FDA regulatory hurdles made its venture-backed business model unsustainable.
Kintsugi, a technology company developing voice biomarkers for mental health, is shutting down its commercial operations. The company says it will make all of its technology and research public.
Kintsugi is shutting down commercial operations and open-sourcing its mental health voice biomarker technology. Grace Chang describes the release as a gift to the global mental health community.
